QuantaPro

QuantaPro enables oncologists to determine—early and in real time—whether chemotherapy will work, using a single drop of blood. Beginning with the ERCC1 chemo-resistance test, the company addresses a long-standing clinical blind spot in oncology while building a scalable, high-margin proteomic testing platform that will expand to other chronic diseases.